Skip to content

Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving

Study to Investigate the Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving at 2 Bar and 4 Bar in Professional Navy Divers

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01496911
Enrollment
24
Registered
2011-12-21
Start date
2012-04-30
Completion date
2012-10-31
Last updated
2013-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Keywords

Diving, Drugs, Antihistamines, Performance

Brief summary

Antihistamines are commonly used and currently levocetirizine is most frequently prescribed in the Netherlands. They are commonly used by divers, to solve ear, nose and throat problems, especially to open tubal passage. However, the effects of these drugs on cognitive performance have not been investigated during diving.The objective of this study is to investigate the effects of levocetirizine, hydroxyzine and placebo on cognitive and psychomotor functioning during controlled simulated diving in a hyperbaric chamber in professional navy divers at 10 mt (2 bar) and 30 mt (4 bar).It is hypothesized that hydroxyzine will produce significant impairment, and that the magnitude of impairment is related to hyperbaric pressure.

Detailed description

This double-blind, randomized, placebo-controlled cross-over study will comprise of 1 training day and 3 test days. Twenty-four healthy male divers from the Royal Netherlands Navy will participate in this study.The objective of this study is to investigate the single dose effects of levocetirizine (5 mg), hydroxyzine (50 mg) and placebo. Visit 1 is a training day, and Visit 2-4 are test days. At the test day, subjects receive one of the three medications. One hour after administration of the drugs, subjects will start with the dive in the recompression chamber. After one hour, medication has reached their peak plasma concentration, and effects can be expected. There will be a wash-out period of at least 7 days between the test days. Subjects will perform one simulated dive at each test day. They first descend in 2 min to a pressure of 4 bar (30 mt), stay for 20 min, the dive continues when they ascend to a pressure of 2 bar (10 mt) with another stay for 20 min. At both depths the 20 min periods are the measuring period to perform the test. At the end they will go to the surface according the decompression profile and stop for 3 min at 9 mt, 8 min at 6 mt and 23 min at 3 mt. These decompression stops are regular for the profile and necessary to prevent decompression sickness.Before and after diving, and at 2 and 4 bar, tests measuring attention, memory, psychomotor, concentration and comprehension ability of the participants are conducted.

Interventions

DRUGLevocetirizine

a single oral dose of 5 mg

a single oral dose of 50 mg

DRUGPlacebo

a single oral dose

Sponsors

Royal Netherlands Navy
CollaboratorUNKNOWN
Utrecht Institute for Pharmaceutical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* male healthy volunteer * He is aged between 18 and 55 years old * BMI between 18 and 30 * Written informed consent * Normal static binocular acuity, corrected or uncorrected * Normal hearing * Possession of a valid divers certificate and medical fit for diving * Be considered as reliable and mentally capable of adhering to the protocol.

Exclusion criteria

* Female * Current drug use * Use of psychoactive medication, including antihistamines * Prior enrolment in the same study * Physical or mental illness * Excessive alcohol use (\>21 alcoholic drinks per week) * Intake of caffeine-containing beverages over 5 glasses per day * Smoker

Design outcomes

Primary

MeasureTime frame
Number of errors on the cognitive testsacute (up to 3.5 hours after treatment administration)

Secondary

MeasureTime frame
Reaction speed on the cognitive testsacute (up to 3.5 hours after treatment administration)

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026